Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of its previously announced underwritten public offering of 6,634,615 shares of its…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.